What Value Do You See Oncology Care Teams, Administrators and Patients Gaining Patient Experience Data?

Dr. Aaron Galaznik, Chief Scientific Officer of Carevive, introduces Carevive’s transformative platform, PROmpt, providing remote symptom monitoring and patient quality of life measurement during cancer treatment. Carevive’s smart data combines routinely assessed patient-reported outcomes with EMR-derived clinical data, ensuring a scalable and actionable approach to bring the patient perspective into cancer treatment.

Published studies and collaborative research with esteemed institutions like the University of Alabama at Birmingham and the University of South Alabama have demonstrated the profound impact of integrating patient-reported outcomes on patient outcomes. PROmpt enables better patient engagement, informed treatment decisions, and empowers remote symptom monitoring between visits. With granular smart data, Carevive opens new avenues for quality improvement and health services research.

Discover how Carevive’s innovative platform can elevate your organization and benefit your patients. Contact us to embark on a journey towards favorable patient outcomes and enhanced cancer care.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…